Shots:
Recently AstraZeneca’s FASENRA (benralizumab) received approval from the US FDA as an add-on maintenance treatment for patients (≥ 6 yrs.) with severe asthma and with an eosinophilic phenotype
Today, at PharmaShots we have with us Donna Carstens, Senior Medical Director Respiratory, Fasenra at AstraZeneca
Donna shares insights from the TATE study an open-label, multinational,…
Shots:
Dupuytren’s disease is a chronic progressive & debilitating fibrosis that impacts hands. There’s an unmet need to treat Dupuytren’s disease, especially when looking for a pharmacological substitute for surgical interventions
Today, at PharmaShots, we had the pleasure to speak with Kurt Harrington, CEO and Founder of Ventoux Biosciences
Kurt shares insights from the preclinical…
Shots:
In the May Edition of the Know Your Investor series, we are focussing on Alexandria Venture Investments, an integral part of Alexandria Real Estate Equities
In 2023, Alexandria Venture Investments invested in 24 companies; 5, 8, 5 & 6 every quarter across 2023 respectively
For a detailed report on all the investments, reach out…
Shots:
Propelled by unceasing innovations and inch-perfect precision, the diagnostic industry is advancing at an astonishing pace
In 2023, the global diagnostic test market size was valued at $210.58B and is envisioned to reach $284.38B by 2033, registering a CAGR of 3.05 percent from 2024 to 2033. Roche reclaims its first position with a revenue…
Shots:
A rare autoimmune condition, Sjögren’s Syndrome is characterized by dry mouth and eye. The condition affects 0.5 to 1% of the global population of which 90% of patients are women
In this reprise of our Disease of the Month report, we bring an illuminating account of Sjögren’s Syndrome with deep dive analysis of epidemiology, market size, disease management, available therapies, patient…
Throughout April PharmaShots was swamped with the heavy traffic of life science updates. As an official media partner to Reuters Events, PharmaShots was present in Barcelona, covering groundbreaking presentations from leading biopharma companies.
Our most-read top 20 section featured reports on Top 20 RNAi Therapeutic Companies, Top 20 Biopharma Deal Terminations of 2023, and Top 20 Biopharma Companies. For…
Shots:
An already established biologic treatment for SEA in the US, EU5 & Japan. Fasenra is now showing exemplary remission for the treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Today, at PharmaShots, we have a distinguished panel of speakers shedding light on advancements under the P-III MANDARA study and the recent publication of the study…
Shots:
PharmaShots has compiled a list of US FDA-approved drugs in the month of April 2024
The US FDA approved a total of 12 new drugs including 11 new molecular entities and 1 biologic leading to the treatments for patients and advances in the healthcare industry
The major highlighted drug was X4 Pharmaceuticals’ Xolremdi for…
Shots:
Bringing innovation and technology to healthcare, the MedTech sector is growing rapidly and transforming the ways diagnosis and treatment are received
With a global market size of $503.2B in 2023, the MedTech sector anticipates reaching $776.4B by 2033 with a CAGR of 4.4 percent. With a staggering revenue of $32.31B, Medtronic ranks first in…
Shots:
Meri Beckwith, Co-Founder of Lindus Health engages in a striking conversation with PharmaShots
Meri talks about bridging the gaps of clinical trials in CNS/Neurology by leveraging LLMs that are trained on nearly a million clinical trial protocols and simple machine learning models to monitor real-time clinical trial data
Meri highlights the importance of multidisciplinary…

